Biomerica, Inc. 10-K FY2026 Annual Report | BMRA | CapEdge

What changedvs. the 10-K/A for 2025 FY — 5 notable changesView full comparison

Rewritten: “MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over…”
Rewritten: “Cash used in operating activities during fiscal 2026 included increases in inventories and accounts receivable of approximately $140,000 and $66,000, respectively, a decrease in accrued compensation of approximately $162,000, and reductions in lease liabilities of approximately…”
Rewritten: “Food, Drug & Cosmetic Act of 1938 (the “FDCA”) regulates medical devices in the United States by classifying them into one of three classes based on the extent of regulation believed necessary to ensure safety and effectiveness. Class I devices are those devices for which safety…”
Rewritten: “2026. The adoption did not have a material impact on our consolidated financial statements but resulted in additional income tax disclosures (see Note 7 of our consolidated financial statements). In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting…”
Rewritten: “Our research and development activities include the development and optimization of immunoassays, enzyme-linked immunosorbent assays (“ELISAs”), rapid diagnostic tests, and related diagnostic technologies. These products are either internally developed, licensed from third…”

Company

Biomerica, Inc.

Form

10-K

Timestamp

5:00 PM Aug 31, 2026

Views

26

Create a free CapEdge Account

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news
Access all data and search results

Actions

Font Size

Search this filing

Table of Contents

Log in or sign up to navigate this filing by section.

Similar Filings

No similar filings found for this document.

Exhibits